130 reports of this reaction
1.5% of all OXYMETAZOLINE HYDROCHLORIDE reports
#15 most reported adverse reaction
EPISTAXIS is the #15 most commonly reported adverse reaction for OXYMETAZOLINE HYDROCHLORIDE, manufactured by Bayer HealthCare LLC.. There are 130 FDA adverse event reports linking OXYMETAZOLINE HYDROCHLORIDE to EPISTAXIS. This represents approximately 1.5% of all 8,811 adverse event reports for this drug.
Patients taking OXYMETAZOLINE HYDROCHLORIDE who experience epistaxis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EPISTAXIS is a less commonly reported adverse event for OXYMETAZOLINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to epistaxis, the following adverse reactions have been reported for OXYMETAZOLINE HYDROCHLORIDE:
The following drugs have also been linked to epistaxis in FDA adverse event reports:
EPISTAXIS has been reported as an adverse event in 130 FDA reports for OXYMETAZOLINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EPISTAXIS accounts for approximately 1.5% of all adverse event reports for OXYMETAZOLINE HYDROCHLORIDE, making it a notable side effect.
If you experience epistaxis while taking OXYMETAZOLINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.